Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study
- 10 January 2007
- journal article
- Published by Springer Science and Business Media LLC in Documenta Ophthalmologica
- Vol. 114 (1), 37-44
- https://doi.org/10.1007/s10633-006-9036-7
Abstract
To evaluate by MFERG and OCT the macular function before and after intravitreal use of bevacizumab (Avastin) in eyes suffering from CNV due to ARMD. Eighteen eyes with subfoveal CNV due to ARMD were studied before and after intravitreal use of bevacizumab with MFERG and OCT. The post treatment follow up was three months. Before treatment, OCT shows an increase of the retinal thickening of the fovea and the electrical response densities in the fovea and parafovea were decreased in all patients. Three months after treatment, OCT showed a real resolution of the subretinal fluid. The electrical responses in the fovea and parafovea remained the same or slightly improved in some cases. The intraocular pressure remained normal and no inflammation was observed. The intravitreal use of bevacizumab may provide anatomical correlates that support the concept of disease amelioration but the functional improvement of the macula three months after treatment is not obvious. However the method is promising and needs further evaluation.Keywords
This publication has 18 references indexed in Scilit:
- New Treatments for AMDOphthalmology, 2006
- Which treatment is best for which AMD patient?British Journal of Ophthalmology, 2006
- Dynamics of Retinal Function after Multiple Photodynamic Therapies in Age-Related Macular Degeneration: A Report of CasesDocumenta Ophthalmologica, 2005
- Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Week Results of an Uncontrolled Open-Label Clinical StudyOphthalmology, 2005
- Pegaptanib for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2004
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNature Reviews Drug Discovery, 2004
- Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—verteporfin in photodynamic therapy report 2American Journal of Ophthalmology, 2001
- CLINICOPATHOLOGIC CORRELATION OF CHOROIDAL NEOVASCULARIZATION DEMONSTRATED BY INDOCYANINE GREEN ANGIOGRAPHY IN A PATIENT WITH RETENTION OF GOOD VISION FOR ALMOST FOUR YEARSRetina, 1994
- Age-related Macular Degeneration Histopathologic StudiesOphthalmology, 1993
- The field topography of ERG components in man—I. The photopic luminance responseVision Research, 1992